Wir sind mit live! Mehr erfahren

Zimmer Biomet

ZBH

Börsenwert 18,1 Mrd. $

94,98 USD

+0,60

0,64 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

94,25

-0,73

0,77 %

1 Tag

0,64 %

5 Tage

6,38 %

1 Monat

-1,86 %

3 Monate

1,31 %

6 Monate

0,21 %

Seit Jahresbeginn

5,51 %

1 Jahr

-4,94 %

5 Jahre

-32,52 %

10 Jahre

-22,74 %

Profil: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Mitarbeiter: 17.000

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 50 %

Neutral 50 %

Negativ 0 %

ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT

Multi-Year Extension to Help Accelerate Adoption of Wireless, Handheld TMINI® System for Use with Zimmer Biomet's Persona® Knee System FREMONT, Calif. and WARSAW, Ind.

ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT

Zacks Investment Research

Should Value Investors Buy Zimmer Biomet (ZBH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Zimmer Biomet (ZBH) Stock?

Zacks Investment Research

Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?

Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results

WARSAW, Ind., Oct. 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its third quarter earnings conference call will be webcast on Wednesday, November 4, 2026, at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results

Zacks Investment Research

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock

Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation

Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and Data WARSAW, Ind.

Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation

Zacks Investment Research

Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?

Zimmer Biomet - Showing Signs Of Life

Zimmer Biomet is seeing structural constant currency sales growth appear. This is driven by transformation factors, R&D and M&A efforts. Earnings growth is lagging sales, but this hopefully should catch up soon.

Zimmer Biomet - Showing Signs Of Life

Zacks Investment Research

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026

WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2026.

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt